XVII CONGRESSO MINEIRO DE PNEUMOLOGIA E CIRURGIA TORÁCICA e VI CONGRESSO MINEIRO DE PNEUMOLOGIA PEDIÁTRICA
1º Dia - 10/10/25
2º Dia - 10/11/25
3º Dia - 10/9/25

O Avanço no Tratamento dos Pacientes com Câncer de Pulmão Avançado Voltar

Flávia Amafal Duarte

Mesa Redonda - Câncer de Pulmão - Leonardo Brand Rodrigues

Artigo Autor(es) Referência
Advances and challenges in the treatment of lung cancer. Li Yuting, Yan Bingshuo, He Shiming Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023 Dec; 169(Dec):115891. doi: 10.1016/j.biopha.2023.115891. pii: S0753-3322(23)01689-X.
Antibody-drug conjugates in advanced lung cancer: Is this a new frontier? Reuss Joshua E, Rosner Samuel, Levy Benjamin P Clinical advances in hematology & oncology : H&O. 2024 Jun; 22(Jun):217-226.
Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study. Zhao Dong, Bi Minghong, Cheng Xiaofei, Wang Shuhong, Cheng Huaidong, Xia Xiaoyang, Chen Huan, Zhang Yanbei, Hu Zhiqiang, Cao Qisheng, Liang Hui, Wang Fan, Min Xuhong, Xu Ling, Feng Kehai, Zhou Jinhua, Li Xinzhong, Wang Rui, Xie Hua, Chen Xiaosi, Gu Kangsheng Frontiers in immunology. 2025 ; 16():1494708. doi: 10.3389/fimmu.2025.1494708. pii: .
Locally Advanced Lung Cancer. Oh Sarah, Botros George N, Patel Milan, Haigentz Missak, Patel Eshan, Kontopidis Iaonnis, Langenfeld John, Deek Matthew P, Jabbour Salma K Hematology/oncology clinics of North America. 2023 Apr; doi: 10.1016/j.hoc.2023.02.007. pii: S0889-8588(23)00019-9.
New promises and challenges in the treatment of advanced non-small-cell lung cancer. Meyer May-Lucie, Fitzgerald Bailey G, Paz-Ares Luis, Cappuzzo Federico, Jänne Pasi A, Peters Solange, Hirsch Fred R Lancet (London, England). 2024 Aug; 404(Aug):803-822. doi: 10.1016/S0140-6736(24)01029-8. pii: S0140-6736(24)01029-8.
Proton beam radiotherapy for patients with early-stage and advanced lung cancer: a narrative review with contemporary clinical recommendations. Chiang Jennifer S, Yu Nathan Y, Daniels Thomas B, Liu Wei, Schild Steven E, Sio Terence T Journal of thoracic disease. 2021 Feb; 13(Feb):1270-1285. doi: 10.21037/jtd-20-2501. pii: .
Real-world data on efficacy and safety of pembrolizumab in the first-line treatment of metastatic lung cancer in patients with PD-L1 expression >0% - a single center experience. Cvijić T, Canjko I, Tomaš I, Kralik K, Perić L, Kotromanović D, Krivdić Dupan Z, Kovač Peić A, Mimica S European review for medical and pharmacological sciences. 2023 Oct; 27(Oct):9213-9225. doi: 10.26355/eurrev_202310_33949. pii: 33949.
Recent advances in therapeutic strategies for non-small cell lung cancer. Su Po-Lan, Furuya Naoki, Asrar Alahmadi, Rolfo Christian, Li Zihai, Carbone David P, He Kai Journal of hematology & oncology. 2025 Mar; 18(Mar):35. doi: 10.1186/s13045-025-01679-1. pii: .
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study. de Marinis F, Kim T M, Bonanno L, Cheng S, Kim S-W, Tiseo M, Chu Q, Proto C, Sacher A, Luo Y-H, Novello S, Hao D, Baik C, Bazhenova L, Lee J S, Cho B C, Cadranel J, Diep T B, Metro G, Narayanan P, Yoneshima Y, de Castro Carpeño J, Baldotto C, Nyhus C, Yang J C-H, Sequist L V, Levy B, Hartmaier R, Igwegbe I, Poole L, Xu W, Ahn M-J Annals of oncology : official journal of the European Society for Medical Oncology. 2025 May; doi: 10.1016/j.annonc.2025.04.003. pii: S0923-7534(25)00157-7.
Top advances in lung cancer, 2021. Mohindra Nisha A, Patel Jyoti D Cancer. 2022 Aug; doi: 10.1002/cncr.34406. pii: .
Top advances of the year: Targeted therapy for lung cancer. Makarem Maisam, Jänne Pasi A Cancer. 2024 Oct; 130(Oct):3239-3250. doi: 10.1002/cncr.35423. pii: .
Update 2025: Management of Non‑Small-Cell Lung Cancer. Jeon Hyein, Wang Shuai, Song Junmin, Gill Harjot, Cheng Haiying Lung. 2025 Mar; 203(Mar):53. doi: 10.1007/s00408-025-00801-x. pii: 53.
Nenhuma revista foi definida para este congresso.